Results 71 to 80 of about 53,685 (285)
InfoMat, EarlyView.This review offers an overview of recent advances in the fundamental properties, synthesis methods, and structural optimization of transition‐metal single‐atom electrocatalysts for electrochemical sensing. It also provides a comprehensive summary of the emerging applications in electrochemical assays based on these materials, along with key challenges ...
Yue Cao +8 more
wiley +1 more source
Interdisciplinary Medicine, EarlyView.This study successfully developed and evaluated BDNF@RVG‐sEVs, a novel brain‐targeted nanomedicine based on hnmMSC‐derived sEVs, designed to overcome the BBB and enhance neurorestoration. By integrating RVG for enhanced brain targeting and encapsulating BDNF for potent neurorepair, our system address the key limitations of the conventional sEVs and ...
Xueting Wang +13 more
wiley +1 more source
Frontiers in Neurology, 2019 Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa +9 more
doaj +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley +1 more source
Effect of Rectal Levodopa Administration: A Case Report
Case Reports in Neurology, 2015 Objective: The aim of this report is to discuss whether or not rectal levodopa administration is useful in some situations. Background: In situations where oral intake of levodopa formulations is not possible, the treatment options of Parkinson's disease
Jolanda M.J. Vogelzang +2 more
doaj +1 more source
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
, 2013 Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic ...
Bargiotas P, Konitsiotis S
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy +16 more
wiley +1 more source
, 2018 Vibhash D Sharma, Kelly E Lyons, Rajesh Pahwa Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA Abstract: Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on ...
Pahwa R, Lyons KE, Sharma VD
core
The Clinical Development of Levodopa Inhalation Powder
, 2023 Oral levodopa is the most effective treatment for Parkinson disease, but OFF periods emerge over time. Gastrointestinal dysfunction and food effects impact levodopa absorption, contributing to unpredictable control of OFF periods. Inhaled levodopa powder
Waters, Cheryl H +4 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño +6 more
wiley +1 more source